Table 2.
Baseline characteristics and final diagnosis for suction technology.
| Procedure | p-value | ||
|---|---|---|---|
| SS group | HWS group | ||
| Age, mean ± SD, y/o | 59.29 ± 11.71 | 56.52 ± 10.16 | 0.323 |
| Sex, n (%) | 0.199 | ||
| Male | 19 (55.9) | 21 (72.4) | |
| Female | 15 (44.1) | 8 (27.6) | |
| Location | 0.282 | ||
| Head and neck, n (%) | 14 (41.2) | 15 (51.7) | |
| Body and tail, n (%) | 19 (55.9) | 11 (37.9) | |
| Diffuse involvement, n (%) | 1 (2.9) | 3 (10.3) | |
| Size of the lesion, mm | 0.948 | ||
| <20 mm | 12 (35.3) | 9 (31.0) | |
| 20–50 mm | 15 (44.1) | 13 (44.8) | |
| >50 mm | 7 (20.6) | 7 (24.1) | |
| Puncture needle | 1.000 | ||
| 19G FNA | 18 (52.9) | 16 (55.2) | |
| 22G FNB | 16 (47.1) | 13 (44.8) | |
| Platelet count (/mm3) | 292298.441 ± 88443.911 | 276241.517 ± 83619.566 | 0.464 |
| Prothrombin index | 1.030 ± 0.108 | 0.977 ± 0.101 | 0.051 |
| Diagnosis following EUS-TA, n (%) | 0.208 | ||
| Pancreatic carcinoma | 8 (23.5) | 9 (31.0) | |
| Chronic pancreatitis | 3 (8.8) | 4 (13.8) | |
| Metastatic carcinoma | 3 (8.8) | 7 (24.1) | |
| Neuroendocrine tumor | 4 (11.8) | 3 (10.3) | |
| Mucinous cystadenoma | 3 (8.8) | 0 (0.0) | |
| Adenosquamous carcinoma | 3 (8.8) | 0 (0.0) | |
| Solid pseudopapillary neoplasm | 2 (5.9) | 1 (3.4) | |
| Lymphoma | 1 (2.9) | 1 (3.4) | |
| Serous cystadenoma | 3 (8.8) | 0 (0.0) | |
| IgG4-related pancreatitis | 0 (0.0) | 2 (6.9) | |
| Non-diagnostic | 4 (11.8) | 2 (6.9) | |